No association seen between estimated R&D investments and treatment costs based on list prices at launch or net prices after one year
For 2018 compared with 2014, mean out-of-pocket cost of naloxone increased by 506 percent among uninsured patients
Under the law, Medicare will now be allowed to negotiate the cost of some drugs; vaccines will be free for Part D recipients
However, 86.6 percent of people with opioid use disorder are not receiving medication treatment
Meta-analyses suggest positive effects of noradrenergic drugs on global cognition, apathy
Increase in methadone-involved deaths in March 2020 not thought to be tied to expanded opioid treatment program take-home policies
Small pilot study suggests suvorexant may improve sleep, reduce opioid withdrawal and craving during buprenorphine/naloxone taper
Trial was the first to test a drug meant to delay or halt mental decline in people who have a genetic predisposition
Relative change from 2016 to 2019 varied from −52.0 percent in Mississippi to −6.9 percent in New Hampshire
At pandemic outset, significant decreases in buprenorphine prescription fills seen for Black, Hispanic patients, but not White patients